Recent work presented at the 2025 annual meeting of American Society of Bone & Mineral Research found that romosozumab significantly outperformed teriparatide and denosumab in improving hip and spine bone strength.
Tony M. Keaveny, PhD
Advertisement
Tony M. Keaveny, PhD, is the Founder and Chief Science Officer of O.N. Diagnostics.
Articles by Tony M. Keaveny, PhD
Advertisement
Latest Updated Articles
Romosozumab outperforms teriparatide and denosumab in bone strengthPublished: September 15th 2025 | Updated: September 16th 2025
- Romosozumab outperforms teriparatide and denosumab in bone strength
Published: September 15th 2025 | Updated: September 16th 2025
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Experts recommend postpartum psychosis be classified as its own disorder
2
NK Receptor Antagonism as Therapeutic Strategy for Vasomotor Symptoms
3
Supporting employees with PCOS: The overlooked opportunity in inclusive fertility benefits
4
Contemporary OB/GYN week in review: PCOS subtypes, fertility prediction, and more
5
